Report of Foreign Issuer (6-k)
March 06 2017 - 1:07PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
06 March
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc (the
'Company'
)
Transaction
notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S A
Hussain
|
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial
Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The
sale of 98,581.776 Ordinary Shares on 6 March 2017 at a price of
£16.8006.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.8006
|
98,581.776
|
|
|
|
|
|
d)
|
Aggregated
information
|
n/a
(single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date of
the transaction
|
2017-03-06
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mrs S G
Hussain
|
b)
|
Position/status
|
PCA of
Mr S A Hussain (President, Global Pharmaceuticals)
|
c)
|
Initial
notification/
amendment
|
Initial
Notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The
sale of 131,418 Ordinary Shares on 6 March 2017 at a price of
£16.835.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.835
|
131,418
|
|
|
|
|
|
d)
|
Aggregated
information
|
n/a
(single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date of
the transaction
|
2017-03-06
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
06, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024